致幻剂与致幻剂辅助心理治疗的精神科应用综述
本文通过系统检索PubMed和PsycINFO,综述了2007年至2019年7月间关于致幻剂(裸盖菇素、LSD、死藤水、MDMA)在精神障碍中临床应用的研究。共纳入14项设计良好的临床试验,证据支持MDMA治疗PTSD和裸盖菇素治疗抑郁及癌症相关焦虑的疗效,但总体证据尚不足以支持FDA批准任何致幻剂常规临床使用。
要点
- 随机临床试验支持MDMA治疗PTSD和裸盖菇素治疗抑郁及癌症相关焦虑的疗效。
- LSD和死藤水的研究为观察性,证据初步但有一定前景。
- 现有证据尚不足以支持FDA批准任何致幻剂用于精神障碍常规临床使用。
核心结论
- 随机临床试验支持MDMA治疗PTSD和裸盖菇素治疗抑郁及癌症相关焦虑的疗效。
- LSD和死藤水的研究为观察性,证据初步但有一定前景。
- 总体证据尚不足以支持FDA批准任何致幻剂用于精神障碍常规临床使用。
研究设计与样本
- 检索PubMed和PsycINFO via Ovid,英文同行评议期刊,2007年至2019年7月1日。
- 检索词包括psilocybin、lysergic acid diethylamide、LSD、ayahuasca、3,4-methylenedioxymethamphetamine、MDMA,限人类研究。
- 共识别1603篇文章,筛选后161篇由两名或以上作者综述。
- 最终识别14篇报告设计良好的临床试验,涉及LSD、MDMA、裸盖菇素和死藤水。
主要发现
- MDMA和裸盖菇素的数据库最显著,分别被FDA指定为PTSD和治疗抵抗性抑郁的「突破性疗法」。
- 随机临床试验支持MDMA治疗PTSD和裸盖菇素治疗抑郁及癌症相关焦虑的疗效。
- LSD和死藤水的研究为观察性,但现有证据提示这些药物可能在特定精神障碍中有治疗效果。
关键数值与推荐
- 14篇临床试验文章评估LSD、MDMA、裸盖菇素和死藤水治疗心境和焦虑障碍、创伤和应激相关障碍、物质相关和成瘾障碍及临终关怀的疗效。
- MDMA被FDA指定为PTSD的「突破性疗法」,裸盖菇素被指定为治疗抵抗性抑郁的「突破性疗法」。
临床怎么用
- 临床可关注MDMA辅助心理治疗用于PTSD和裸盖菇素辅助心理治疗用于抑郁及癌症相关焦虑的研究进展。
- LSD和死藤水的临床使用证据尚不充分,需谨慎对待。
- 目前任何致幻剂均未获FDA批准用于精神障碍常规临床使用。
局限性
- 总体数据库不足以支持FDA批准任何致幻剂用于精神障碍常规临床使用。
- LSD和死藤水的研究仅为观察性,证据初步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. METHODS: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxymethamphetamine," and "MDMA," in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms "clinical trial," "therapy," or "imaging" in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. RESULTS: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as "breakthrough therapies" for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. CONCLUSIONS: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
引用
- Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020. PMID: 32098487. doi:10.1176/appi.ajp.2019.19010035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。